National Cancer Institute says new FDA draft guidance will subject a substantial number of additional patients to dose optimization studies of ineffective or non-viable agents. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
